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1  | INTRODUCTION
The rapid aging of the Japanese population means that an increasing 
number of patients and their families are facing the end of life.1,2 
However, reports indicate that approximately 70% of terminally ill 
patients who can never be cured experience difficulty making pa‐
tient‐oriented decisions.3 It is particularly difficult to make a decision 
about medical procedures immediately before death.4 One way to 
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Abstract
Background: Advance directives (ADs) are seldom discussed between primary care 
physicians (PCPs) and their patients, especially those with noncancer diseases. The 
aim was to identify the factors associated with discussing AD by noncancer patients 
with their physicians.
Methods:  This cross‐sectional study was conducted in a hospital or clinic from 
October to December 2017. Physicians chose eligible noncancer patients aged 
20 years or older to respond to an anonymous self‐completed questionnaire inquir‐
ing about the objective variable “I want to discuss AD with my doctor,” as well as basic 
characteristics, and facilitators and barriers to discussing AD identified in previous 
studies. The physicians responded to a survey comprising the Palliative Performance 
Scale (PPS) and inquiring about the disease category for each patient. Data were ana‐
lyzed using binomial logistic regression analysis.
Results: A total of 270 patients (valid response rate, 79.6%) were included. Multivariate 
analysis identified a period of visit to the study site ≥ 3 years (odds ratio [OR], 2.07; 
95% confidence interval [CI], 1.05‐4.10), physicians who are very good at taking care 
of patients’ disease (OR, 12.68; 95% CI, 1.12‐143.22), and patients’ worry about their 
quality of life (QOL) in the future (OR, 2.69; 95% CI, 1.30‐5.57) as facilitators for 
discussing AD with physicians, and PPS ≤ 90 (OR, 0.51; 95% CI, 0.26‐0.98) as a 
barrier.
Conclusions: Our study indicates that patients’ future QOL concerns, a long period of 
visit to a hospital, and the presence of physical symptoms were associated with the 
willingness of noncancer patients to discuss AD with PCPs.
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overcome this issue is to establish advance directives (ADs).5 An AD 
is defined as an oral or written statement in which a person, prior to 
his or her possible state of incapacitation, gives instructions regard‐
ing medical treatment.5 Japanese people are increasingly required to 
discuss ADs and to consider a patient‐oriented end of life while they 
are still healthy enough to express their intentions.
Primary care physicians (PCPs) play an important role in discuss‐
ing ADs with patients. Primary care physicians can consult with pa‐
tients about ADs to direct them to appropriate end‐of‐life care6 and 
encourage them to establish ADs.7 However, patients tend to hesi‐
tate to discuss ADs with medical practitioners including their PCPs3,8 
despite hoping to do so.9 As a result, ADs are not shared between 
PCPs and their patients. Some reasons for this are associated with dif‐
ficulties discussing ADs between physicians and patients.10 From the 
physicians’ perspective, a lack of training in communication11 and un‐
certainty about prognostic accuracy12 are key barriers. From the pa‐
tients’ perspective, anxiety and denial of disease are key barriers.13,14
Most previous studies regarding discussions about ADs were 
conducted in cancer patients. Noncancer diseases, compared to 
cancer, have clinical courses that make it more difficult to predict 
the patients’ prognoses.15,16 Nevertheless, it is just as important to 
investigate discussions about ADs in noncancer patients as it is in 
cancer patients because the number of noncancer disease cases, like 
cancer cases, is increasing. However, few studies have been con‐
ducted on noncancer patients in primary care settings (PCSs), where 
patients may want to discuss ADs. Identification of facilitators and 
barriers to discussing AD for noncancer patients may increase their 
opportunities to discuss ADs with their PCPs.
Therefore, the present study was conducted to identify the fac‐
tors associated with discussing AD by noncancer patients with their 
physicians.
2  | METHOD
2.1 | Study design
This was a cross‐sectional study conducted using an anonymous 
self‐completed questionnaire survey by patients and a background 
survey on patients by their physicians.
2.2 | Setting and participants
Surveys were conducted in the outpatient section of the General 
Internal Medicine/Family Medicine department at a small 30‐bed 
hospital or clinic in a PCS. Both the hospital and clinic are public 
healthcare institutions in the same prefecture, located 30 minutes 
by car from the city center, which has a population of 200 000 peo‐
ple. Both medical institutions provide primary care. At both sites, 
one physician treated an average of 20 patients per half day, the 
consultation time per patient was around 10 minutes, and no other 
medical staff were present in the room during an examination.
Study participants included noncancer patients who visited the 
study site for at least 6 months and their physicians. All physician 
participants were Japan Primary Care Association (JPCA)‐certified 
family physicians or JPCA diplomates in primary care. There were 
four JPCA‐certified family physicians in the hospital and one in the 
clinic. There was one JPCA diplomate in primary care in the hos‐
pital and one in the clinic. Patients who met the following criteria 
were eligible to participate in the study: age 20 years or older, and 
no history of malignancy or any previous malignancy for which the 
patient was no longer receiving treatment at the time of the study. 
The following patients were excluded from the study: those who did 
not consent to participate in the study; those who completed the 
questionnaire more than twice; and those who were unable to com‐
plete the questionnaire due to dementia or physical disability.
2.3 | Survey methods
Physicians who attended the outpatient section of the study sites for 
at least 6 months, including during the study period from October to 
December 2017, and agreed to participate in the survey were desig‐
nated physician participants. At least two visits to the same physician 
were used to define continuous contact between a patient‐physician 
pair. Given that prescription medications in Japan can be prescribed 
for up to 3 months in one visit, and most patients consulted the same 
physician, consecutive visits within 6 months was used as an index 
for continuous contact. Patients who visited the outpatient section 
attended by the physician participants during the 1‐month survey 
were continuously sampled at the hospital/clinic. The receptionist 
confirmed that patients satisfied the criteria of “over 20 years old” 
and “consecutive visits within 6 months.” Physician participants sub‐
sequently checked patients’ eligibility by confirming that “the patient 
had no malignancy that needed treatment” based on the patients' 
medical chart and that “it was a regular visit" and "the patient had not 
participated in the study” before a medical examination. At the end 
of the medical examination, physician participants judged whether 
the patients were capable of completing a questionnaire by them‐
selves. Among those judged capable, the physician participants asked 
eligible patients to participate in the questionnaire‐based study and 
provided each patient with a patient questionnaire with written in‐
structions. Those who were considered incapable were excluded. A 
nurse or the receptionist explained the questionnaire and responses 
to the patients. The physicians were not informed of whether the pa‐
tients consented to the study or of their responses, and the patients 
were informed of this fact. Patients who consented to participate in 
the study completed the questionnaire and dropped it into a desig‐
nated box outside the examination room. The physicians completed 
a physician questionnaire after the medical examination. The lead 
investigator matched serially numbered patient questionnaire forms 
with corresponding physician questionnaire forms.
2.4 | Survey items
In this study, AD was defined in the questionnaire as acceptable or 
unacceptable treatment when a patient is too critically ill or deterio‐
rating to communicate their intentions.5
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In Japan, there is currently no valid scale for assessing factors 
related to the willingness of patients to discuss AD with their phy‐
sicians. Therefore, survey items were selected by referring to previ‐
ous studies and by discussion among the authors. The survey items 
listed below were selected based on the facilitators and barriers to 
patients’ discussion with physicians about AD reported in previous 
studies17‒20 in order of clinical significance.
2.5 | Patient questionnaire
The following patient characteristics were investigated: age, gender, 
education level, self‐perceived health status (five levels: 1 = poor 
to 5 = good), and period of visit to the study site (<1 year, 1 year 
to <2 years, 2 years to <3 years, 3 years to <4 years, ≥4 years). 
Regarding AD‐related experiences, participants were inquired about 
the presence or absence of experience with caring for the dying 
and experience with proxy decisions and asked to indicate the ex‐
tent to which the following items applied to them using a 5‐point 
Likert‐type scale (1: not at all, 2: slightly, 3: moderately, 4: very, 5: 
extremely): “I have previously thought about AD,” “I have discussed 
AD with my family or friends,” and “I have discussed AD with my 
doctor.” Patients were also asked to use the 5‐point Likert‐type scale 
to respond to the item “I want to discuss AD with my doctor,” which 
was used as the objective variable in the survey. In addition, patients 
used the same scale to respond to the following six facilitators and 
three barriers to discussing AD reported in previous studies: facilita‐
tors: “It is important for me to think about AD,” “My doctor cares 
about me as a person,” “I trust my doctor,” “My doctor is very good 
at taking care of my disease,” “I worry about my quality of life in the 
future,” “I worry that I could be a burden on my family and friends if 
I got very sick”; and barriers: “I would rather concentrate on staying 
alive than talk about death,” “I feel that talking about death can bring 
death closer,” and “I'm not sure which doctor will provide care if I get 
very sick”.17‒20
2.6 | Physician questionnaire
The general condition of each patient surveyed was assessed using 
the Palliative Performance Scale (PPS).21 The PPS is an observer‐
rated tool used to assess five functional dimensions: ambulation, 
activity level and evidence of disease, self‐care, oral intake, and level 
of consciousness. The PPS is divided into 11 levels from 0% (death) 
to 100% (healthy) in 10 percent increments.21 The disease being 
treated or followed up was categorized by the physician participants 
according to the International Classification of Primary Care, Second 
Edition (ICPC‐2).22
2.7 | Statistical analyses
Patients’ education level was classified into two categories: high 
school diploma or lower and two‐year college diploma or higher. 
Self‐perceived health status, period of visit to the study site, and PPS 
score were analyzed as ordinal variables. Reponses to all questions 
answered on the 5‐point Likert‐type scale were classified into two 
categories: not applicable, for responses of “1: not at all” and “2: 
slightly”; and applicable, for responses of “3: moderately,” “4: very,” 
and “5: extremely.” The objective variable was “I want to discuss AD 
with my doctor,” and the explanatory variables were age, gender, 
education level, self‐perceived health status, period of visit to the 
study site, experience with caring for the dying, experience with 
proxy decisions, “I have previously thought about AD,” “It is impor‐
tant for me to think about AD,” facilitators and barriers to patients 
discussing AD with physicians, disease category, and PPS score. 
After descriptive statistics were determined for each variable, uni‐
variate analyses were performed for age using the Mann‐Whitney U 
test and for nominal and ordinal variables using the chi‐square test 
or Fisher’s exact test at a significance level of <0.05.
In addition to significant variables identified by univariate analy‐
ses, and age and gender, which are potential confounders, patients’ 
general condition in PCSs was considered relevant.23 We employed 
the PPS as a validated tool for assessing patients’ general condition 
in the palliative care field.24 However, there were minimal differ‐
ences in the general condition of patient participants receiving pri‐
mary care, which is usually provided to relatively healthy individuals. 
Therefore, we concluded that it may be more clinically meaningful to 
use the PPS as a binomial qualitative tool based on the presence or 
absence of symptoms, rather than a quantitative tool. Accordingly, 
PPS scores were classified into two groups: scores of 100, indicating 
no symptoms, and scores of 90 or less, indicating the presence of 
symptoms. A binomial logistic regression analysis model was used 
to analyze differences between the symptom‐free and symptomatic 
groups, with a significance level of <0.05. In view of potential multi‐
collinearity, significant explanatory variables identified by univariate 
analysis were reviewed based on the correlation coefficients of sim‐
ilar variables to determine which variables to include in the binomial 
logistic regression analysis model. Statistical analysis was performed 
using SPSS ver.22 software (IBM Japan Co.,Ltd.,Tokyo, Japan).
This study was conducted with prior approval from the Ethics 
Committee of the Faculty of Medicine, University of Tsukuba (No. 
1152‐1).
3  | RESULTS
A survey flowchart is presented in Figure 1. Of the 339 patients 
surveyed, three did not submit a questionnaire form, while the 
remaining 336 responded to the questionnaire. A total of 295 
patients (87.0%) who responded to the objective variable “I want 
to discuss AD with my doctor” were included in the univariate 
analyses, of which 270 (79.6%) were included in the multivari‐
ate analysis after excluding 25 patients who had missing data on 
any question in the patient and/or physician questionnaire. The 
characteristics of patients included in the univariate analyses are 
shown in Table 1. The mean ± SD age was 69.9 ± 11.3 years, 130 
patients (44.1%) were male, 64 patients (21.7%) had an educa‐
tion level equivalent to a two‐year college diploma or higher, 101 
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patients (34.4%) had a period of visit to the study site of ≥3 years, 
222 patients (75.3%) had a PPS score of 100, and the most com‐
mon self‐perceived health status was 3 (147 patients, 49.8%). 
Major underlying diseases were cardiovascular diseases in 214 pa‐
tients (72.5%) and endocrine/metabolic and nutritional diseases in 
164 patients (55.6%).
Of the 295 patient participants, 74.2% replied positively to “I 
want to discuss AD with my doctor” (Figure 2). The distribution of 
other items such as experience with discussing AD, and facilitator 
and barrier factors are shown in Figure 2.
3.1 | Univariate analyses
The results of univariate analyses between the objective variable 
and the explanatory variables are presented in Table 1. No analysis 
was performed for the disease categories “pregnancy, childbear‐
ing, family planning” and “female genital system,” which were not 
relevant to this patient population. Explanatory variables with a 
significance level of <0.05 were “I have previously thought about 
AD” (P < 0.01), “It is important for me to think about AD” (P < 0.01), 
“My doctor cares about me as a person” (P < 0.01), “I trust my doc‐
tor” (P = 0.02), “My doctor is very good at taking care of my disease” 
(P = 0.02), “I worry about my quality of life in the future” (P < 0.01), 
“I would rather concentrate on staying alive than talk about death” 
(P = 0.01), and “I feel that talking about death can bring death closer” 
(P = 0.01). The chi‐square test also identified the period of visit to 
the study site as a significant factor (P = 0.03). No significant correla‐
tion was observed between the objective variable and age, gender, 
education level, self‐perceived health status, PPS score, experience 
with caring for the dying, experience with proxy decisions, or indi‐
vidual disease categories. After the univariate analyses, frequency 
distributions were determined using histograms to perform a multi‐
variate analysis, with the period of visit to the study site being cat‐
egorized into two groups (≥3, <3 years).
3.2 | Multivariate analysis
For the objective variable, binomial logistic regression analysis was 
performed using an analytical model that included the following ex‐
planatory variables: age and gender; basic characteristics that may 
be confounders; significant variables identified by univariate analy‐
ses; and period of visit to the study site (≥3, <3 years). The analyti‐
cal model did not include “I have previously thought about AD” and 
“It is important for me to think about AD” as explanatory variables 
because they were considered intermediate factors of the objec‐
tive variable “I want to discuss AD with my doctor.” Additionally, 
the model included “My doctor is very good at taking care of my 
disease,” which was selected among three variables with a Pearson 
correlation coefficient of ≥0.4 and a two‐sided P‐value of <0.01, in‐
cluding “My doctor cares about me as a person” and “I trust my doc‐
tor.” The results are presented in Table 2. Period of visit to the study 
site (reference, <3 years; odds ratio [OR], 2.07; 95% confidence in‐
terval [CI], 1.05‐4.10; P = 0.04), PPS score (reference, PPS 100; OR, 
0.51; 95% CI, 0.26‐0.98; P = 0.04), “My doctor is very good at tak‐
ing care of my disease” (reference, not applicable; OR, 12.68; 95% 
CI, 1.12‐143.22; P = 0.04), and “I worry about my quality of life in 
the future” (reference, not applicable; OR, 2.69; 95% CI, 1.30‐5.57; 
P = 0.01) were identified as significant variables.
4  | DISCUSSION
Among noncancer patients who visited an outpatient hospital or 
clinic in a PCS for at least 6 months in Japan, willingness to discuss 
ADs with their physicians was significantly positively correlated with 
a period of visit to the study site of ≥3 years, belief that “My doctor 
is very good at taking care of my disease,” and feelings of “I worry 
about my quality of life in the future” and was significantly nega‐
tively correlated with a PPS score of ≤90.
The relationship between the period of visit to a study site and 
willingness of patients to discuss AD was not investigated in pre‐
vious studies, including in a cross‐sectional study in cancer and 
noncancer outpatients who visited a family physician or a specialist 
for at least 18 months17 and a cross‐sectional study in primary care 
outpatients aged 18 years or older.25 It would have been difficult to 
follow up patients for over 3 years if the studies involved terminally 
ill cancer patients. The present study suggests that a certain period 
of time may be required to build a consultative relationship between 
physicians and patients to encourage patients to discuss AD with 
their physicians. A previous report suggested that patients want to 
F I G U R E  1   Survey flow of patients
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TA B L E  1   Patients' characteristics, predictors, and univariate analysis results
Variable Total n = 295
I want to discuss AD with my doctor
Yes, n = 219(%) No, n = 76 (%) P‐value
Age (mean ± SD) 69.9 ± 11.3 69.6 ± 10.8 67.0 ± 12.7 0.08a
<65 72 (24.4) 47 (21.7) 25 (32.9) 0.05b
≥65 221 (74.9) 170 (78.3) 51 (67.1)
Data missing 2 (0.7)
Gender (reference: male)
Female 161 (54.6) 119 (55.3) 42 (55.3) 0.99b
Male 130 (44.1) 96 (44.7) 34 (44.7)
Data missing 4 (1.3)
Educational level
<Junior high school 70 (24.1) 55 (25.6) 15 (20.0) 0.65b
High school diploma 156 (53.8) 111 (51.6) 45 (60.0)
Two‐year college or vocational school 30 (10.3) 23 (10.7) 7 (9.3)
Four‐year college degree 34 (11.7) 26 (12.1) 8 (10.7)
Data missing 5 (1.7)
(reference: ≤High school diploma)
≥Two‐year college 64 (21.7) 49 (22.8) 15 (20.0) 0.62b
≤High school diploma 226 (76.6) 166 (77.2) 60 (80.0)
Self‐perceived health status
1: poor 1 (0.3) 1 (0.5) 0 (0) 0.94b
2 41 (13.9) 32 (14.8) 9 (11.8)
3 147 (49.8) 108 (50.0) 39 (51.3)
4 67 (22.7) 49 (22.7) 18 (23.7)
5: good 36 (12.2) 26 (12.0) 10 (13.2)
Data missing 3 (1.0)
Palliative Performance Scale (PPS) score
50 1 (0.3) 1 (0.5) 0 (0) 0.77b
60 3 (1.0) 2 (0.9) 1 (1.3)
70 4 (1.4) 3 (1.4) 1 (1.3)
80 17 (5.8) 12 (5.5) 5 (6.8)
90 45 (15.2) 30 (13.8) 15 (20.3)
100 222 (75.3) 170 (78.0) 52 (70.3)
Data missing 3 (1.0)
(reference: 100)
≤90 70 (23.7) 48 (22.0) 22 (29.7) 0.06b
100 222 (75.3) 170 (78.0) 52 (70.3)
Period of visit to the study site 
Over 6 mo to <1 y 32 (10.8) 22 (10.1) 10 (13.1) 0.03b
Over 1 y to < 2 y 76 (25.8) 57 (26.1) 19 (25.0)
Over 2 y to < 3 y 85 (28.8) 55 (25.2) 30 (39.5)
Over 3 y to <4 y 28 (9.5) 26 (11.9) 2 (2.6)
Over 4 y 73 (24.7) 58 (26.6) 15 (19.7)
Data missing 1 (0.3)
(reference: <3 y)
(Continues)
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Variable Total n = 295
I want to discuss AD with my doctor
Yes, n = 219(%) No, n = 76 (%) P‐value
Over 3 y 101 (34.4) 84 (38.5) 17 (22.4) 0.01b
<3 y 193 (65.6) 134 (61.5) 59 (77.6)
I have previously thought about AD
Applicable 185 (62.7) 160 (74.8) 25 (34.7) <0.01b
Not applicable 101 (34.2) 54 (25.2) 47 (65.3)
Data missing 9 (3.1)
I have experience caring for the dying
Yes 243 (82.4) 183 (84.7) 60 (78.9) 0.25b
No 49 (16.6) 33 (15.3) 16 (21.1)
Data missing 3 (1.0)
I have experience with proxy decisions
Yes 137 (46.4) 103 (48.6) 34 (45.9) 0.70b
No 149 (50.5) 109 (51.4) 40 (54.1)
Data missing 9 (3.1)
Facilitators
It is important for me to think about AD
Applicable 253 (85.8) 208 (96.3) 45 (60.0) <0.01b
Not applicable 38 (12.9) 8 (3.7) 30 (40.0)
Data missing 4 (1.4)
My doctor cares about me as a person
Applicable 277 (93.9) 205 (100) 72 (94.7) <0.01c
Not applicable 4 (1.4) 0 (0)  4 (5.3)
Data missing 14 (4.7)
I trust my doctor
Applicable 291 (98.6) 218 (100) 73 (96.1) 0.02c
Not applicable 3 (1.0) 0 (0) 3 (3.9)
Data missing 1 (0.3)
My doctor is very good at taking care of my disease
Applicable 284 (96.3) 214 (75.4) 70 (24.6) 0.02c
Not applicable 5 (1.7) 1 (20.0) 4 (80.0)
Data missing 6 (2.0)
I worry about my quality of life in the future
Applicable 233 (79.0) 183 (86.7) 50 (67.6) <0.01b
Not applicable 52 (17.6) 28 (13.3) 24 (33.4)
Data missing 10 (3.4)
I worry that I could be a burden on my family and friends if I got very sick
Applicable 273 (92.5) 206 (94.9) 67 (89.3) 0.08c
Not applicable 19 (6.5) 11 (5.1) 8 (10.7)
Data missing 3 (1.0)
Barriers
I would rather concentrate on staying alive than talk about death
Applicable 265 (89.8) 203 (94.9) 62 (84.9) 0.01b
Not applicable 23 (7.8) 12 (5.1) 11 (15.1)
Data missing 7 (2.4)
TA B L E  1   (Continued)
(Continues)
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Variable Total n = 295
I want to discuss AD with my doctor
Yes, n = 219(%) No, n = 76 (%) P‐value
I feel that talking about death can bring death closer
Applicable 178 (60.3) 142 (66.4) 36 (48.0) 0.01b
Not applicable 111 (37.6) 72 (33.6) 39 (52.0)
Data missing 6 (2.0)
I'm not sure which doctor will provide care if I get very sick
Applicable 212 (71.9) 164 (77.4) 48 (65.8) 0.05b
Not applicable 73 (24.7) 48 (22.6) 25 (34.2)
Data missing 10 (3.4)
ICPC‐2 category
General and unspecified
Applicable 2 (0.7) 2 (0.9) 0 (0) 0.55c
Not applicable 293 (99.3) 217 (99.1) 76 (100)
Blood, blood‐forming organ and immune mechanism
Applicable 2 (0.7) 2 (0.9) 0 (0) 0.55c
Not applicable 293 (99.3) 217 (99.1) 76 (100)
Digestive
Applicable 74 (25.1) 49 (22.4) 25 (32.9) 0.07b
Not applicable 221 (74.9) 170 (77.6) 51 (67.1)
Eye
Applicable 2 (0.7) 2 (0.9) 0 (0) 0.55c
Not applicable 293 (99.3) 217 (99.1) 76 (100)
Ear
Applicable 2 (0.7) 2 (0.9) 0 (0) 0.55c
Not applicable 293 (99.3) 217 (99.1) 76 (100)
Cardiovascular
Applicable 214 (72.5) 160 (73.1) 54 (71.1) 0.74b
Not applicable 81 (27.5) 59 ((26.9) 22 (28.9)
Musculoskeletal
Applicable 40 (13.6) 28 (12.8) 12 (15.8) 0.51b
Not applicable 255 (86.4) 191 (87.2) 64 (84.2)
Neurological
Applicable 23 (7.8) 16 (7.3) 7 (9.2) 0.59b
Not applicable 272 (92.2) 203 (92.7) 69 (90.8)
Psychological
Applicable 74 (25.1) 56 (25.6) 18 (23.7) 0.74b
Not applicable 221 (74.9) 163 (74.4) 58 (76.3)
Respiratory
Applicable 14 (4.7) 10 (4.6) 4 (5.3) 0.51c
Not applicable 281 (95.3) 209 (95.4) 72 (94.7)
Skin
Applicable 4 (1.4) 3 (1.4) 1 (1.3) 0.73c
Not applicable 291 (98.6) 216 (98.6) 75 (98.7)
TA B L E  1   (Continued)
(Continues)
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discuss AD with physicians who understand them very well.26 This 
is supported by our finding that the belief that “My doctor is very 
good at taking care of my disease” was a facilitator for discussing 
AD. Confidence established between physicians and patients may 
therefore contribute to willingness of patients to discuss AD with 
their physicians.
“I worry about my quality of life in the future” was also identified 
as a facilitator for discussing AD in a previous study.17 However, in 
contrast to the previous finding that patients with anxiety or de‐
pression tended to want to discuss AD,17 we found no association 
with such psychological diseases in this study. This may be due to 
differences in the proportion of patients with various psychological 
diseases between the studies. In the present study, the psycho‐
logical disease category included not only depression and anxiety, 
but also insomnia, and many patients with psychological disease 
at outpatient primary care clinics, which are often visited by pa‐
tients complaining of insomnia,27 had insomnia without depression 
or anxiety. Therefore, the lack of an association between psycho‐
logical diseases and willingness to discuss AD in this study may be 
due to a low rate of depression among participant patients in these 
PCSs.
We also identified a PPS score ≤ 90 as a significant barrier to 
discussing AD. PPS score ≤ 90 indicates that physicians identified 
symptoms in patients. Therefore, our finding suggests that noncan‐
cer primary care patients with symptoms tended to be reluctant to 
discuss AD with their physicians. This may be partly explained by 
differences in the curability of diseases. Cancer patients coping with 
incurable disease after an informed diagnosis of cancer may have 
an opportunity to discuss AD as their symptoms or physical func‐
tion deteriorate.28,29 In contrast, noncancer patients with slow pro‐
gressive diseases that follow a course of exacerbation and remission 
may feel that the disease has been cured when it is only transiently 
relieved. It is therefore conceivable that these patients are often 
optimistic about transient symptom relief and avoid discussing AD 
when they experience symptoms. The present study suggests that 
noncancer patients who do not have symptoms associated with their 
chronic disease may be more inclined to discuss AD while noncancer 
patients with deteriorating physical function may be reluctant to talk 
about AD with their physicians.
To facilitate patient‐oriented end of life, it is important to provide 
sufficient opportunities for patients to voice their intentions even 
while they are still healthy. However, establishing ADs too early leads 
to ambiguity and uncertainty, with ADs tending to be most uncertain 
in the general healthy population, followed by outpatients and then 
inpatients.30 Therefore, physicians should be increasingly aware 
of chances to establish ADs to ensure that they are discussed in a 
timely manner.31 To avoid missing out on such a chance, the present 
study suggests that physicians should discuss ADs with noncancer 
patients before the development of symptoms following a diagnosis.
The present study has several limitations. First, given that rep‐
resentative related factors were selected from those identified in 
previous studies, other potentially related factors may have been 
missed. Second, this was a cross‐sectional study and was therefore 
not designed to demonstrate a causal relationship. Third, there may 
have been a degree of sampling bias because the study participants 
were only from two local areas. As we did not set any criteria for 
how physicians should determine patients’ capability to complete 
the questionnaire, the physician participants may have assessed 
each patient's capability based on clinical observations. Further 
studies are needed to generalize the results to the entire Japanese 
population. Fourth, there may be a reporting bias associated with 
the frequency of visits. Patients with a higher frequency of visits 
may have increased desire to discuss AD. Further, we did not deter‐
mine the number of visits by patients prior to the survey. Fifth, only 
five patients answered “No” to the item “My doctor is good at taking 
care of my disease,” and the range of its CI was large, which may have 
Variable Total n = 295
I want to discuss AD with my doctor
Yes, n = 219(%) No, n = 76 (%) P‐value
Endocrine/metabolic and nutritional
Applicable 164 (55.6) 126 (57.5) 38 (50.0) 0.26b
Not applicable 131 (44.4) 93 (42.5) 38 (50.0)
Urological
Applicable 10 (3.4) 6 (2.7) 4 (5.3) 0.24c
Not applicable 285 (96.6) 213 (97.3) 72 (94.7)
Male genital
Applicable 1 (0.3) 1 (0.5) 0 (0) 0.74c
Not applicable 294 (99.7) 218 (99.5) 76 (100)
Social problems
Applicable 4 (1.4) 4 (1.8) 0 (0) 0.30c
Not applicable 291 (98.6) 215 (98.2) 76 (100)
aUnpaired t test. 
bChi‐square test. 
cFisher's exact test. 
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reduced the stability of the multivariate model. However, we think 
that it was important to examine this factor because previous stud‐
ies18‒20 have shown that patients’ feelings toward their physician is 
a key factor in their willingness to conduct AD discussions with their 
physician. Sixth, we analyzed data from the patient participants as a 
single group even though there were some differences in participant 
characteristics between the two study sites. Differences and simi‐
larities in participant characteristics between the two study sites are 
TA B L E  2   Factors associated with “I want to discuss AD with my doctor” (binomial logistic regression analysis)
Variable Reference
Univariate Multivariate
P‐valuea
Crude 
OR 95% CI
Adjusted 
OR 95% CI
Age <65 y 1.77 1.00‐3.16 1.74 0.90‐3.37 0.10
Gender Male 1.00 0.59‐1.70 0.98 0.53‐1.80 0.98
Period of visit to the study site <3 y 2.18 1.19‐3.98 2.07 1.05‐4.10 0.04
Palliative Performance Scale score 100 0.67 0.37‐1.21 0.51 0.26‐0.98 0.04
Facilitators
My doctor is very good at taking care of my 
disease
Not applicable 12.23 1.34‐111.23 12.68 1.12‐143.22 0.04
I worry about my quality of life in the future Not applicable 3.14 1.67‐5.88 2.69 1.30‐5.57 0.01
Barriers
I would rather concentrate on staying alive than 
talk about death
Not applicable 3.00 1.26‐7.14 1.38 0.41‐4.65 0.60
I feel that talking about death can bring death 
closer
Not applicable 2.14 1.25‐3.65 1.55 0.83‐2.93 0.17
CI, confidence interval; OR, odds ratio.
aP‐value was calculated for multivariate analysis. 
The bold values indicate P‐value is significant level of <0.05. 
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summarized in the Table S1. There were no differences in participant 
characteristics between the two locations except for mean age and 
period of visit to the study sites. In accordance with findings in the 
literature,17‒20 we hypothesized that the physician‐patient relation‐
ship was a more significant factor for patients discussing AD with 
their physician than study location. Therefore, we analyzed the pa‐
tient participants from the two sites as a single group. In the future, 
differences in patient characteristics among locations should be ac‐
counted for by increasing the sample size and comparison with find‐
ings from other studies. Finally, the PPS has been validated to assess 
the condition of patients receiving palliative care,24 but not those 
receiving primary care. Nevertheless, the use of PPS in primary care 
was clinically meaningful because we compared the results of this 
study with those of studies in cancer patients. Further follow‐up of 
noncancer patients in multiple PCSs over time may reveal changes in 
willingness toward discussing AD and the underlying reasons.
5  | CONCLUSIONS
Our study indicates that a patient’s future QOL concerns, a long pe‐
riod of visit to a hospital, and the presence of physical symptoms are 
associated with the willingness of noncancer patients to discuss ADs 
with PCPs. These findings will be useful for developing strategies to 
encourage patients to discuss ADs with their physicians.
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